Products Teriparatide (PTH 1-34)
Teriparatide (PTH 1-34) Phase 2/3 Completed 📈 Rising Menopause, Fracture, Osteoporosis
Aug 20, 2008 → Jan 3, 2012
About Teriparatide (PTH 1-34) Teriparatide (PTH 1-34) is a phase 2/3 stage product being developed by Eli Lilly for Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00697463. Target conditions include Menopause, Fracture, Osteoporosis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00697463 Phase 2/3 Completed Aug 20, 2008 Jan 3, 2012 Menopause
Product Company Stage Hype Score atomoxetine + placebo Eli Lilly Pre-clinical Fezolinetant + Placebo Astellas Pharma Phase 2 Cetrorelix Shionogi Pre-clinical Eszopiclone + Placebo Sumitomo Pharma Pre-clinical Comparator: placebo + Comparator: Estrace Merck Phase 1 esmirtazapine + Placebo Merck Phase 3 Marketed low dose hormone replacement therapy Novo Nordisk Pre-clinical 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) Novo Nordisk Pre-clinical 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Approved estradiol, 10 mcg + estradiol, 25 mcg + placebo Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Pre-clinical estradiol, 10 mcg Novo Nordisk Phase 3 estradiol, 10 mcg + estradiol, 25 mcg Novo Nordisk Phase 1 estradiol, 10 mcg Novo Nordisk Phase 3 2 mg estradiol / 1 mg norethisterone acetate (NETA) Novo Nordisk Phase 1 estradiol, 25 mcg Novo Nordisk Phase 3 estradiol, 25 mcg Novo Nordisk Phase 3 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo Novo Nordisk Phase 3 estradiol, 25 mcg + estradiol, 25 mcg Novo Nordisk Phase 1
Other Products from Eli Lilly